6 Aug
2021

US legislators have anti-competitive pharma IP strategies in their sights

With the Biden Administration pushing for action on abusive strategies, several pieces of legislation with implications for life sciences patents are also working their way through Congress

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth